Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2015 (2015), Article ID 102430, 6 pages
http://dx.doi.org/10.1155/2015/102430
Research Article

The Application of GeneXpert MTB/RIF for Smear-Negative TB Diagnosis as a Fee-Paying Service at a South Asian General Hospital

1Oxford University Clinical Research Unit, Patan Hospital, Patan Academy of Health Sciences, P.O. Box 252, Kathmandu, Nepal
2Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK
3Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam
4Department of Microbiology and Immunology, Patan Hospital, Patan Academy of Health Sciences, P.O. Box 252, Kathmandu, Nepal

Received 25 September 2014; Revised 12 February 2015; Accepted 18 March 2015

Academic Editor: Vincent Jarlier

Copyright © 2015 Poojan Shrestha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, Global Tuberculosis Report, WHO/HTM/TB/2013.11, World Health Organization, Geneva, Switzerland, 2013, http://www.who.int/tb/publications/global_report/en/.
  2. D. B. Young, M. D. Perkins, K. Duncan, and C. E. Barry III, “Confronting the scientific obstacles to global control of tuberculosis,” The Journal of Clinical Investigation, vol. 118, no. 4, pp. 1255–1265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. M. D. Perkins and J. Cunningham, “Facing the crisis: improving the diagnosis of tuberculosis in the HIV era,” Journal of Infectious Diseases, vol. 196, supplement 1, pp. S15–S27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. L. M. Parsons, Á. Somoskövi, C. Gutierrez et al., “Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities,” Clinical Microbiology Reviews, vol. 24, no. 2, pp. 314–350, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Urdea, L. A. Penny, S. S. Olmsted et al., “Requirements for high impact diagnostics in the developing world,” Nature, vol. 444, supplement 1, pp. 73–79, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Helb, M. Jones, E. Story et al., “Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology,” Journal of Clinical Microbiology, vol. 48, no. 1, pp. 229–237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. P. P. Banada, S. K. Sivasubramani, R. Blakemore et al., “Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings,” Journal of Clinical Microbiology, vol. 48, no. 10, pp. 3551–3557, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. C. C. Boehme, P. Nabeta, D. Hillemann et al., “Rapid molecular detection of tuberculosis and rifampin resistance,” The New England Journal of Medicine, vol. 363, no. 11, pp. 1005–1015, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. H. H. El-Hajj, S. A. E. Marras, S. Tyagi, F. R. Kramer, and D. Alland, “Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons,” Journal of Clinical Microbiology, vol. 39, no. 11, pp. 4131–4137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. D. Lawn and M. P. Nicol, “Xpert MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance,” Future Microbiology, vol. 6, no. 9, pp. 1067–1082, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. R. Steingart, H. Sohn, I. Schiller et al., “Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults,” The Cochrane Database of Systematic Reviews, vol. 1, Article ID CD009593, 2014. View at Publisher · View at Google Scholar
  12. World Health Organization, Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System—Policy Statement, World Health Organization, Geneva, Switzerland, 2011.
  13. World Health Organization, Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children. Policy Update, World Health Organization, Geneva, Switzerland, 2013.
  14. World Health Organization, Global Health Observatory Data Repository, World Health Organization, 2012, http://apps.who.int/gho/data/view.main.1920ALL?lang=en.
  15. National Tuberculosis Programme Nepal, Annual Report 2012/13, 2014, http://nepalntp.gov.np/index.php?view=publication.
  16. S. D. Lawn, P. Mwaba, M. Bates et al., “Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test,” The Lancet Infectious Diseases, vol. 13, no. 4, pp. 349–361, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. D. W. Dowdy, A. Cattamanchi, K. R. Steingart, and M. Pai, “Is scale-up worth it? Challenges in economic analysis of diagnostic tests for tuberculosis,” PLoS Medicine, vol. 8, no. 7, Article ID e1001063, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Vassall, S. van Kampen, H. Sohn et al., “Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis,” PLoS Medicine, vol. 8, no. 11, Article ID e1001120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. N. A. Baloch and M. Pai, “Tuberculosis control: business models for the private sector,” The Lancet Infectious Diseases, vol. 12, no. 8, pp. 579–580, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Theron, J. Peter, D. Dowdy, I. Langley, S. B. Squire, and K. Dheda, “Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?” The Lancet Infectious Diseases, vol. 14, no. 6, pp. 527–532, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. International Union against Tuberculosis and Lung Diseases Paris, Technical Guide: Sputum Examination for Tuberculosis by Direct Microscopy in Low Income Countries, International Union against Tuberculosis and Lung Diseases Paris, 5th edition, 2000.
  22. S. Saleem, I. Shabbir, R. Iqbal, and S. U. Khan, “Value of three sputum smears microscopy in diagnosis of pulmonary tuberculosis,” Pakistan Journal of Medical Research, vol. 46, no. 4, pp. 1–5, 2007. View at Google Scholar
  23. J. Seni, B. R. Kidenya, E. Obassy et al., “Low sputum smear positive tuberculosis among pulmonary tuberculosis suspects in a tertiary hospital in Mwanza, Tanzania,” Tanzania Journal of Health Research, vol. 14, no. 2, pp. 1–9, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Rachow, A. Zumla, N. Heinrich et al., “Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay—a clinical validation study,” PLoS ONE, vol. 6, no. 6, Article ID e20458, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. C. C. Boehme, M. P. Nicol, P. Nabeta et al., “Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study,” The Lancet, vol. 377, no. 9776, pp. 1495–1505, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. R. Steingart, A. Ramsay, D. W. Dowdy, and M. Pai, “Serological tests for the diagnosis of active tuberculosis: relevance for India,” Indian Journal of Medical Research, vol. 135, no. 5, pp. 695–702, 2012. View at Google Scholar · View at Scopus